Ani Pharmaceutic Stock Price, News & Analysis

ANI Pharmaceuticals (Nasdaq: ANIP) announced a Board leadership change on Dec 1, 2025. Patrick D. Walsh has stepped down as Chairman and will retire from the board after completing his current term at the Company’s 2026 Annual Meeting of Stockholders. The Board unanimously elected Thomas J. Haughey, a director since May 2018, as the next Chairman. Mr. Haughey will relinquish the role of Chair of the Audit and Finance Committee and remain on that committee and the Nominating and Corporate Governance Committee.

Jeanne Thoma, a director since August 2020, will become Chair of the Audit and Finance Committee. Management framed the transition as orderly and focused on continuity while the company expands its Rare Disease business.

ANI Pharmaceuticals (Nasdaq: ANIP) announced that Chief Executive Officer Nikhil Lalwani will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET. The event will be available live and via archived webcast on the company website under Investors > Events and Presentations. The replay will be accessible for 90 days following the live presentation.

ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.

The live webcast and an archived replay will be available via the company’s investor website under Events and Presentations and will remain accessible for 90 days.

ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q3 2025 net revenues of $227.8M, a 53.6% year‑over‑year increase, driven by Purified Cortrophin Gel $101.9M (up 93.8%). The company reported record adjusted non‑GAAP EBITDA of $59.6M and adjusted non‑GAAP diluted EPS of $2.04, with GAAP diluted EPS of $1.13.

ANI raised full‑year 2025 guidance to $854M–$873M total net revenue, adjusted non‑GAAP EBITDA of $221M–$228M, and adjusted non‑GAAP diluted EPS of $7.37–$7.64. Rare Disease is expected to represent about 50% of 2025 net revenues, including revised Cortrophin Gel guidance of $347M–$352M (≈75%–78% growth).

ANI Pharmaceuticals (Nasdaq: ANIP) will release its third quarter 2025 financial results on Friday, November 7, 2025 prior to market open.

A conference call with Nikhil Lalwani (CEO), Stephen P. Carey (CFO) and Chris Mutz (Head of Rare Disease) will be held on November 7, 2025 at 8:30 a.m. ET. Investors can join by dialing the U.S. toll-free number 800-267-6316 using conference ID 5120265 or via live webcast at www.anipharmaceuticals.com under the Investors section.

A replay will be available about two hours after the call and remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.

ANI Pharmaceuticals (Nasdaq: ANIP) announced that results from the NEW DAY clinical trial of ILUVIEN (fluocinolone acetonide 0.19 mg) for diabetic macular edema will be presented in a late-breaking oral session at the American Academy of Ophthalmology (AAO) 2025 Retina Subspecialty Day on October 17, 2025 at 4:39 pm ET.

The release reiterates that NEW DAY results were previously reported and will be further disseminated at multiple meetings; it also restates ILUVIEN's indication for DME in patients previously treated with corticosteroids who did not have a clinically significant intraocular pressure rise, and summarizes key safety data including intraocular pressure and cataract incidence from the trials.

ANI Pharmaceuticals (NASDAQ:ANIP) has announced its participation in two upcoming investor conferences. CEO Nikhil Lalwani and the executive team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 9:00 AM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET.

Investors can access both live and archived webcasts through the company's website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replays will remain available for 90 days.

ANI Pharmaceuticals (NASDAQ:ANIP) reported exceptional Q2 2025 results with record-breaking performance across key metrics. The company achieved total net revenues of $211.4 million, representing 53.1% year-over-year growth. Their Rare Disease segment, led by Cortrophin Gel with $81.6 million in revenue (66% YoY growth), was a major contributor.

The company's Generics business generated $90.3 million in revenue, up 22.1% YoY. ANI delivered record quarterly adjusted EBITDA of $54.1 million, a 62.8% increase, and achieved adjusted non-GAAP diluted EPS of $1.80.

Based on strong performance, ANI raised its 2025 guidance, now expecting total revenues of $818-843 million and adjusted non-GAAP EBITDA of $213-223 million. Rare Disease revenues are projected to represent approximately 50% of total company revenues in 2025.

ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its second quarter 2025 financial results announcement for Friday, August 8, 2025, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results.

Key executives participating in the call include CEO Nikhil Lalwani, CFO Stephen P. Carey, Head of Rare Disease Chris Mutz, and Chief Medical Officer Mary Pao, M.D., Ph.D. Investors can access the call via toll-free number 800-343-4136 using conference ID 5034065. A webcast will be available on the company's website under the Investors section.